(Q34637268)

English

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial (English)

1 reference

Europe PubMed Central

3 August 2017

phase III clinical trial

0 references

radiation therapy

0 references

1 reference

based on heuristic

inferred from title

Michael Pfreundschuh

25

object named as

Michael Pfreundschuh

0 references

Hartmut Döhner

12

object named as

Hartmut Döhner

1 reference

Europe PubMed Central

3 August 2017

10

object named as

Michael Hallek

1 reference

Europe PubMed Central

3 August 2017

Andreas Bockisch

18

object named as

Andreas Bockisch

1 reference

Europe PubMed Central

3 August 2017

German Hodgkin Study Group

32

object named as

German Hodgkin Study Group

1 reference

Europe PubMed Central

3 August 2017

Christoph Renner

5

object named as

Christoph Renner

1 reference

Europe PubMed Central

3 August 2017

author name string

Andreas Engert

1

1 reference

Europe PubMed Central

3 August 2017

Heinz Haverkamp

2

1 reference

Europe PubMed Central

3 August 2017

Carsten Kobe

3

1 reference

Europe PubMed Central

3 August 2017

Jana Markova

4

1 reference

Europe PubMed Central

3 August 2017

Antony Ho

6

1 reference

Europe PubMed Central

3 August 2017

Josée Zijlstra

7

1 reference

Europe PubMed Central

3 August 2017

Zdenek Král

8

1 reference

Europe PubMed Central

3 August 2017

Michael Fuchs

9

1 reference

Europe PubMed Central

3 August 2017

Lothar Kanz

11

1 reference

Europe PubMed Central

3 August 2017

Bernd Dörken

13

1 reference

Europe PubMed Central

3 August 2017

Nicole Engel

14

1 reference

Europe PubMed Central

3 August 2017

Max Topp

15

1 reference

Europe PubMed Central

3 August 2017

Susanne Klutmann

16

1 reference

Europe PubMed Central

3 August 2017

Holger Amthauer

17

1 reference

Europe PubMed Central

3 August 2017

Regine Kluge

19

1 reference

Europe PubMed Central

3 August 2017

Clemens Kratochwil

20

1 reference

Europe PubMed Central

3 August 2017

Otmar Schober

21

1 reference

Europe PubMed Central

3 August 2017

Richard Greil

22

1 reference

Europe PubMed Central

3 August 2017

Reinhard Andreesen

23

1 reference

Europe PubMed Central

3 August 2017

Michael Kneba

24

1 reference

Europe PubMed Central

3 August 2017

Harald Stein

26

1 reference

Europe PubMed Central

3 August 2017

Hans Theodor Eich

27

1 reference

Europe PubMed Central

3 August 2017

Rolf-Peter Müller

28

1 reference

Europe PubMed Central

3 August 2017

Markus Dietlein

29

1 reference

Europe PubMed Central

3 August 2017

Peter Borchmann

30

1 reference

Europe PubMed Central

3 August 2017

Volker Diehl

31

1 reference

Europe PubMed Central

3 August 2017

Swiss Group for Clinical Cancer Research

33

1 reference

Europe PubMed Central

3 August 2017

Arbeitsgemeinschaft Medikamentöse Tumortherapie

34

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

4 April 2012

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

379

1 reference

Europe PubMed Central

3 August 2017

1791-1799

1 reference

Europe PubMed Central

3 August 2017

9828

1 reference

Europe PubMed Central

3 August 2017

State-of-the-art therapeutics: Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term cause-specific mortality of patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 t

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of leukemia after chemotherapy and radiation treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961940-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)61940-5

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34637268&oldid=2017491101"